PVCT Provectus Biopharmaceuticals - Correlation between Tumor Mutational Burden and Objective Response Rate with Anti–PD-1 or Anti-PD–L - PVCT Provectus Biopharmaceuticals - InvestorVillage
PVCT Provectus Biopharmaceuticals
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: PVCT Provectus Biopharmaceuticals   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  4315 of 4597  at  7/11/2019 7:36:31 AM  by

leave_the_gun


 In response to msg 4314 by  Take_The_Canolis
view thread

Re: Correlation between Tumor Mutational Burden and Objective Response Rate with Anti–PD-1 or Anti-PD–L1 Therapy in 27 Tumor Types

  I could be wrong because I'm only guessing. But I think we get bought before we get FDA approval.
 
But I agree with Canis about each indication being approved separately for specific combo treatments instead of having the FDA approve some umbrella combo treatment that uses one combo to treat all appropriate cancer indications. But this very much works in our favor and I think PRH agrees. As we've seen over the last 1.5 years is PVCT starting numerous P1 trials or expanded cohorts for different indications. If TTC is correct about MUM being the one that is closest to getting FDA approval, then that might be what makes BP move. PRH's ability to show BP that PV-10 in combo will work in other indications other than MUM is where PRH are going to have leverage to negotiate a higher buyout price. Each indication that PV-10 can treat could add significant value to the buyout over the single indication the they initially chose to move on. If one BP wants PV-10 for one combo with their drug and another BP wants PV-10 for their combo, all the better for negotiations. PRH are setting this up and timing things perfectly.
 
But TTC could very well be correct if PVCT gains AA or BTD for an indication. That would be more of a sure thing/less risk for BP to buy at that point. It's important to have as much data about other indications before this happens to maximize price negotiation leverage.
 
Also, I'm VERY excited about the PH-10 clarification. I'd love to see BP buy PV-10  instead of the entire company all at once.  Then we could take our massive cash position to maximize PH-10 value to it's fullest. But, getting money out of PH-10 sooner in order to expand PV-10 studies probably makes more sense.
 
But once again, I agree with Canis in his statement that this is the most interesting and most exciting Press Release that PRH has given the public and I'm VERY excited at where we're headed as a company.
 
I'll be adding more shares.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 7     Views: 192
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
4317 Re: Correlation between Tumor Mutational Burden and Objective Response Rate with Anti–PD-1 or Anti-PD–L1 Therapy in 27 Tumor Types Hombre77 3 7/11/2019 10:04:05 AM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...